U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. FDA Technology Transfer Program
  4. Licensing and Collaboration Opportunities
  5. Filovirus Vaccines and Diagnostics Based on Glycoprotein-Fc Fusion Proteins
  1. FDA Technology Transfer Program

Filovirus Vaccines and Diagnostics Based on Glycoprotein-Fc Fusion Proteins

Filovirus Vaccines and Diagnostics Based on Glycoprotein-Fc Fusion Proteins

Ebola virus is a member of the Filoviridae, a family of viruses classified as “Category A” bioterrorism agents that cause severe hemorrhagic fever in humans and nonhuman primates with high morbidity and mortality rates up to 90%. This invention provides an efficacious Filovirus subunit vaccine based on a recombinant protein consisting of the extracellular domain of the Filovirus glycoprotein fused to an Fc Fragment of human immunoglobulin (FiloGP-Fc). Vaccination with FiloGP-Fc elicited humoral and cellular immunity against Filoviruses. The FiloGP-Fc vaccine induced antibodies that bound and neutralized replication-competent recombinant G-deleted Vesicular Stomatitis Virus containing the Filovirus GP (rVSV-FiloGP), and protected animals against Filovirus lethal challenge. Also described are cellular and humoral immunity tests as well as rVSV-FiloGP neutralization tests to evaluate anti-Filovirus immune responses in individuals.

Potential Commercial Applications:

  • Vaccines for protection against infections by Ebola Virus and other Filoviruses.
  • Diagnostic tests for cellular and humoral immunity based on FiloGP-Fc and rVSV-FiloGP to evaluate anti-Filovirus immune responses in vaccinated and infected animals and individuals.

Competitive Advantages:

Filovirus vaccine candidates based on virus-like particles and virus vectors are currently under development by others. However, efficacious subunit vaccines have not yet been developed. The FiloGP-Fc fusion protein described in this invention has the advantage of resembling the native glycoprotein expressed at the surface of cells and viral particles. Thus, in addition to vaccines, the soluble FiloGP-Fc fusion proteins are ideal substrates to evaluate immune responses in animals and vaccinees.

Gerardo Kaplan
Krishnamurthy Konduru
Sina Bavari
David Bradfute

Intellectual Property:
PCT Application No. PCT/US2011/058418
US Application No. 13/882,041
US Application No. 14/704,792
Several International Patent applications filed

Konduru K, et al. PMID 21329775

Licensing Contact:
Bill Ronnenberg, JD-MIP, MS
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
Email: FDAInventionlicensing@fda.hhs.gov
Phone: 240-402-4561

OTT Reference No: E-222-2010/0
Updated: August 5, 2015